REMS Changing Pharma Approaches

June 2010
Pharmaceutical Representative;Jun2010, Vol. 40 Issue 6, p11
The article reports on the move of the U.S. Food and Drug Administration (FDA) to require the implementation of Risk Evaluation and Mitigation Strategies (REMS) on most new drugs and biotechnology therapies.


Related Articles

  • GSK and Genmab obtain EU positive opinion for leukemia drug.  // PharmaWatch: Cancer;Mar2010, Vol. 9 Issue 3, p11 

    The article announces the reports released by GlaxoSmithKline (GSK) that the U.S. Food and Drug Administration (FDA) has approved the used of Tykerb as a first-line, all-oral treatment for women with metastatic breast cancer.

  • FDA Panel Hands Amgen Mixed Bag in Osteoporosis, Cancer. Young, Donna // BioWorld Today;8/14/2009, Vol. 20 Issue 156, p1 

    This article reports that the U.S. Food and Drug Administration (FDA) has approved Amgen Inc's denosumab for treating osteoporosis in postmenupausal women. However the FDA also rejected denosumab as a therapy for preventing the disease in the population. In addition, the FDA also denied the drug...

  • Berinert Wins Race to the FDA's HAE Finish Line.  // Bioworld Week;10/19/2009, Vol. 17 Issue 42, p3 

    The article reports that Berinert, a C1-esterase inhibitor from King of Prussia, Pennsylvania-based CSL Behring LLC, was approved by the U.S. Food and Drug Administration (FDA). Berinert is reportedly the first approved therapy for acute attacks in patients with hereditary angioedema (HAE). The...

  • Return to sender. Fox, Jeffrey L // Nature Biotechnology;Sep2008, Vol. 26 Issue 9, p961 

    The article discusses an announcement by the U.S. Food and Drug Administration (FDA) in July 2008, regarding a change in their notification process, to companies whose applications for their therapeutic products are not approved. The FDA will issue letters to companies whose drugs can not be...

  • OSI and Genentech's lung cancer drug obtains FDA extended review.  // PharmaWatch: Cancer;Mar2010, Vol. 9 Issue 3, p11 

    The article announces the report released by OSI Pharmaceuticals Inc. that the U.S. Food and Drug Administration (FDA) has extended the review period for the supplemental new drug application (NDA) for Tarceva as a first-line maintenance therapy in advanced non-small cell lung cancer.

  • FDA challenges stem-cell clinic. Cyranoski, David // Nature;8/19/2010, Vol. 466 Issue 7309, p909 

    The article reports on Regenerative Sciences Inc. as the U.S. Food and Drug Administration (FDA) questions its treatment practice provided to patients through the use of stem cells. It states that the conflict between Regenerative Sciences and FDA springs from FDA's claim that stem cell...

  • Fertile is fine. Boyce, Nell // New Scientist;03/20/99, Vol. 161 Issue 2178, p22 

    Reports the reconsideration by the United States Food and Drug Administration (FDA) on a policy of restricting gene testing on sterile people. Allowances for gene therapy; Details of tests on animals using viruses or other vectors to deliver therapeutic DNA; Attack of the policy at a March 1999...

  • Pipeline.  // Medical Marketing & Media;Mar2006, Vol. 41 Issue 3, p12 

    The article presents pharmaceutical companies which have been given approval by the Food & Drug Administration for their newly developed pharmaceutical products in the U.S. Among the companies were Merck & Co. Inc., Genetech Inc., Biogen Idec Inc., Sucampo Pharmaceuticals Inc., and CV...

  • Prescription ads next on FDA list. Colford, S.W. // Advertising Age;8/26/91, Vol. 62 Issue 35, p32 

    Examines Food & Drug Administration (FDA) plans to tighten regulations on drug advertising and various promotional practices. Principal concerns of Commissioner David Kessler; Present regulations of consumer ads for prescription drugs.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics